Drugs / RJ026
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06992661 | May 2025 → Dec 2026 expected | interstitial lung disease | Ruijin Hospital | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RJ026 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06992661 ↗ |
| Route | Inhaled | “RJ026 inhaled powder, 4 mg, inhalation” NCT06992661 ↗ |